"Le Centre Hospitalier de Périgueux, établissement public de santé, se situe en Dordogne, il est l'établissement de santé publique de référence pour le territoire (près de 415 000 habitants). Il possède tout l’équipement médico-technique et les compétences nécessaires pour assurer une prise en charge médicale et chirurgicale optimale des patients. Le CHP, un acteur majeur en cancérologie sur le territoire, ouvert aux coopérations et intégré aux réseaux régionaux. Un plan directeur de modernisation des bâtiments a été mis en place pour créer de nouveaux espaces et optimiser l’accueil des patients : construction d'un nouveau bâtiment de médecine (180 lits supplémentaires), 10 000 m² neufs et une restructuration pour une surface de 6 000 m²."

During the past decade, Service de Pneumologie-Allergologie; Centre Hospitalier Général conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Service de Pneumologie-Allergologie; Centre Hospitalier Général" #1 collaborator was "Groupe Francais De Pneumo-Cancerologie" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Service de Pneumologie-Allergologie; Centre Hospitalier Général" are "Carcinoma, Non-Small-Cell Lung" (1 trials) and "Non Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Service de Pneumologie-Allergologie; Centre Hospitalier Général" in a lesser frequency.

Most popular intervention types in "Service de Pneumologie-Allergologie; Centre Hospitalier Général" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Alimta®" (1 trials), "Docetaxel" (1 trials), "Erlotinib + docetaxel" (1 trials) and "Taxotere®" (1 trials). Other intervention names were less common.

The vast majority of trials in "Service de Pneumologie-Allergologie; Centre Hospitalier Général" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Service de Pneumologie-Allergologie; Centre Hospitalier Général". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Service de Pneumologie-Allergologie; Centre Hospitalier Général, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Service de Pneumologie-Allergologie; Centre Hospitalier Général, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".